Phase 2
Completed N=75
Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia
Source: ClinicalTrials.gov NCT01213524 ↗Enrolled (actual)
75
Serious AEs
0.0%
Results posted
Sep 2020
Primary outcomePrimary: Preferred Brand Smoke Intake (CO) — 3.30; 3.16; 9.07; 10.54 ppm
Summary
The objective of this study is to investigate the relative contributions of nicotine replacement and sensorimotor replacement (i.e., smoking denicotinized cigarettes) on abstinence-induced smoking urges, withdrawal-related negative affect, psychiatric symptoms, cognitive task performance and 90-min ad libitum usual-brand smoking behavior in smokers with schizophrenia and non-psychiatric smokers.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Preferred Brand Smoke Intake (CO) |
3.30; 3.16; 9.07; 10.54; 5.12 | — |
| SECONDARY Questionnaire on Smoking Urges - Brief Scale (QSU-Brief) |
32.02; 37.92; 67.08; 74.13; 24.48 | — |
Eligibility Criteria
Inclusion Criteria
- schizophrenia or no psychiatric illness
- 18 and older
- men and women
- cigarette smokers, 20-50 cigarettes per day
- would like to quit someday
Exclusion Criteria
- medical conditions excluding transdermal nicotine replacement
- pregnancy or lactation
Data sourced from ClinicalTrials.gov (NCT01213524). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.